In a report released today, Joseph Thome from TD Cowen maintained a Hold rating on Allakos (ALLK – Research Report). The company’s shares closed today at $1.80.
According to TipRanks, Thome is an analyst with an average return of -11.6% and a 30.88% success rate. Thome covers the Healthcare sector, focusing on stocks such as Aerovate Therapeutics, Jazz Pharmaceuticals, and United Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Allakos with a $11.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $8.73 and a one-year low of $1.70. Currently, Allakos has an average volume of 1.09M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allakos (ALLK) Company Description:
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.
Read More on ALLK:
